Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-132
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
PTEN-AKT/NF-ĪŗB signaling pathway
Cancer name
Breast Cancer
Cancer site
Breast
Treatment type
Chemotherapy
Drug
Doxorubicin
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
Our findings are among the first to demonstrate a novel aspect of the miR-132/-212-PTEN-AKT/NF-ĪŗB-BCRP pathway in the generation of breast cancer resistance and provides a potential method to reverse drug resistance.
Tissue resource
breast cancer tissue specimens treated with neoadjuvant chemotherapy
breast cancer tissue specimens treated with neoadjuvant chemotherapy
human embryonic kidney cell lines HEK-293T
human embryonic kidney cell lines HEK-293T
Experiment
qRT-PCR,Luciferase reporter assay
Institute
Nanjing Maternity and Child Health Care Hospital
Chinese Academy of Sciences
Country
China
China
Continent
Asia
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.